Vaccines for bovine tuberculosis: Current views and future prospects

Jayne C. Hope*, H. Martin Vordermeier

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Citations (SciVal)


Bovine tuberculosis, caused by Mycobacterium bovis, is rapidly increasing in cattle herds in developed countries such as the UK, New Zealand and the USA. In addition, persistence of M. bovis in other parts of the world may account for up to 10% of cases of human tuberculosis. Thus, a rise in the number of M. bovis infections poses an increased human health risk and is also a major economic problem. In the UK, the incidence of bovine tuberculosis continues to rise despite the use of a skin test and slaughter control policy, highlighting the need for an effective vaccination strategy to control the spread of disease. The only vaccine currently available for human, (and bovine), tuberculosis is Bacillus Calmette-Guérin, which is known to have variable efficacy for both species. In this article, the authors discuss potential strategies by which Bacillus Calmette-Guérin vaccination may be improved to allow highly efficacious vaccination of cattle. These strategies are also highly applicable to the fight against tuberculosis in humans.

Original languageEnglish
Pages (from-to)891-903
Number of pages13
JournalExpert Review of Vaccines
Issue number6
Publication statusPublished - 01 Dec 2005


  • Bacillus Calmette-Guérin
  • Bovine tuberculosis
  • Immunodiagnosis
  • Vaccination


Dive into the research topics of 'Vaccines for bovine tuberculosis: Current views and future prospects'. Together they form a unique fingerprint.

Cite this